Explore by Category

FDA Grants Orphan Drug Status to New CD38 Antibody Redirecting Molecule (ARM) Myeloma Therapy

MYELOMA NEWS - September 18, 2020

The FDA has granted Orphan Drug designation to a new type of myeloma therapy called an Antibody Redirecting Molecule (ARM) targeting CD38. The orphan drug ... Read More

MRD Negativity is Better than Stringent Complete Response (sCR) to Determine Myeloma Patient Outcomes

MYELOMA NEWS - September 17, 2020

In a head-to-head study comparing minimal residual disease (MRD) testing vs. using the "stringent complete response" measurement, MRD indicated a more... Read More

New Ways to Use Our Own T Cells to Treat Myeloma

MYELOMA NEWS - September 14, 2020

Most of us have been reading about CAR-T treatments over the past few years to treat a variety of hematological malignancies. Two CAR-T products have been on th... Read More

Ninlaro with Dex and Revlimid Extends Survival for Newly Diagnosed, Transplant Ineligible Myeloma Patients

MYELOMA NEWS - September 11, 2020

New study results showed that the triplet combination including Ninlaro, lenalidomide and dex increased progression free survival for newly diagnosed myeloma pa... Read More

More Good News for Newly Diagnosed, High Risk Myeloma Patients

MYELOMA NEWS - September 11, 2020

Unfortunately, some of us are or have been tagged as high-risk myeloma patients (and I am one of them). There is some good news that has been reported from Germ... Read More

New Rules for the Centers for Medicare and Medicaid Services on CAR T Therapy

MYELOMA NEWS - September 04, 2020

The Centers for Medicare and Medicaid Services (CMS) recently approved new rules for the use of CAR T treatment for Medicare and Medicaid payment... Read More

The Best Dose of Lenalidomide as Maintenance Therapy in Multiple Myeloma

MYELOMA NEWS - August 24, 2020

In the first study of high dose vs. low dose lenalidomide maintenance, German researchers found that a 10-15mg dose of lenalidomide was most effective in e... Read More

FDA Clears New Use of Kyprolis with Daratumuamb and Dex for Relapsed Multiple Myeloma Patients

MYELOMA NEWS - August 20, 2020

Today the FDA approved the use of Kyprolis (carfilzomib) in a new combination with DARZALEX (daratumumab) and dexamethasone (also called DKd). The approval cove... Read More

How IVig Boosts the Immune System and Kills Multiple Myeloma

MYELOMA NEWS - August 19, 2020

Myeloma patients can often have low levels of normal antibodies that fight infection. Those low levels can lead to issues with recurring infections. If antibody... Read More

Something New to Know about Allo (Donor) CAR Ts

MYELOMA NEWS - August 12, 2020

The CAR-T technology that we have become familiar with starts with harvested T-cells from a patient. These T-cells are then shipped to a processing center where... Read More

Belantamab Mafodotin Receives FDA Approval for Relapsed Multiple Myeloma

MYELOMA NEWS - August 06, 2020

GlaxoSmithKline's belantamab mafodotin (commercial name "BLENREP") has received FDA approval for the treatment of patients with relapsed or refrac... Read More

Which Myeloma Patients Have the Best Outcomes? New Study Shows Key Findings.

MYELOMA NEWS - August 06, 2020

We hear a lot about high risk genetic features in myeloma, but what about patients who have better-than-average outcomes? In a recent study, it was fo... Read More

BMS and bluebird bio Submit Biologics License Application to FDA for CAR T Therapy

MYELOMA NEWS - July 30, 2020

Bristol Myers Squibb and bluebird bio announced their submission for a Biologics License Application (BLA) to the FDA for the approval of the bb2121 CAR T thera... Read More


Thanks to our site sponsors: